CODEXIS INC (CDXS) Fundamental Analysis & Valuation

NASDAQ:CDXS • US1920051067

Current stock price

2.21 USD
+0.23 (+11.62%)
At close:
2.2 USD
-0.01 (-0.45%)
After Hours:

This CDXS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CDXS Profitability Analysis

1.1 Basic Checks

  • CDXS had negative earnings in the past year.
  • In the past year CDXS has reported a negative cash flow from operations.
  • CDXS had negative earnings in each of the past 5 years.
  • CDXS had negative operating cash flow in 4 of the past 5 years.
CDXS Yearly Net Income VS EBIT VS OCF VS FCFCDXS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M

1.2 Ratios

  • CDXS has a worse Return On Assets (-29.75%) than 77.19% of its industry peers.
  • CDXS's Return On Equity of -87.03% is on the low side compared to the rest of the industry. CDXS is outperformed by 80.70% of its industry peers.
Industry RankSector Rank
ROA -29.75%
ROE -87.03%
ROIC N/A
ROA(3y)-43.13%
ROA(5y)-30.29%
ROE(3y)-90.86%
ROE(5y)-61.75%
ROIC(3y)N/A
ROIC(5y)N/A
CDXS Yearly ROA, ROE, ROICCDXS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80

1.3 Margins

  • The Gross Margin of CDXS (86.73%) is better than 98.25% of its industry peers.
  • In the last couple of years the Gross Margin of CDXS has grown nicely.
  • CDXS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.12%
GM growth 5Y1.62%
CDXS Yearly Profit, Operating, Gross MarginsCDXS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. CDXS Health Analysis

2.1 Basic Checks

  • CDXS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CDXS has been increased compared to 1 year ago.
  • Compared to 5 years ago, CDXS has more shares outstanding
  • Compared to 1 year ago, CDXS has a worse debt to assets ratio.
CDXS Yearly Shares OutstandingCDXS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
CDXS Yearly Total Debt VS Total AssetsCDXS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • CDXS has an Altman-Z score of -4.44. This is a bad value and indicates that CDXS is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of CDXS (-4.44) is worse than 85.96% of its industry peers.
  • A Debt/Equity ratio of 0.79 indicates that CDXS is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.79, CDXS is not doing good in the industry: 77.19% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Altman-Z -4.44
ROIC/WACCN/A
WACC11.14%
CDXS Yearly LT Debt VS Equity VS FCFCDXS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 3.82 indicates that CDXS has no problem at all paying its short term obligations.
  • The Current ratio of CDXS (3.82) is better than 64.91% of its industry peers.
  • A Quick Ratio of 3.75 indicates that CDXS has no problem at all paying its short term obligations.
  • CDXS's Quick ratio of 3.75 is fine compared to the rest of the industry. CDXS outperforms 70.18% of its industry peers.
Industry RankSector Rank
Current Ratio 3.82
Quick Ratio 3.75
CDXS Yearly Current Assets VS Current LiabilitesCDXS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. CDXS Growth Analysis

3.1 Past

  • CDXS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.22%, which is quite impressive.
  • CDXS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.61%.
  • Measured over the past years, CDXS shows a small growth in Revenue. The Revenue has been growing by 0.37% on average per year.
EPS 1Y (TTM)42.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%184.62%
Revenue 1Y (TTM)18.61%
Revenue growth 3Y-20.22%
Revenue growth 5Y0.37%
Sales Q2Q%81.34%

3.2 Future

  • Based on estimates for the next years, CDXS will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.77% on average per year.
  • CDXS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 25.46% yearly.
EPS Next Y21.54%
EPS Next 2Y27.57%
EPS Next 3Y23.47%
EPS Next 5Y12.77%
Revenue Next Year10.49%
Revenue Next 2Y12.35%
Revenue Next 3Y16.33%
Revenue Next 5Y25.46%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CDXS Yearly Revenue VS EstimatesCDXS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M 500M
CDXS Yearly EPS VS EstimatesCDXS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 0.5 -0.5 1 -1

More info and screens

Find the best growth stocksShow best growing peers

1

4. CDXS Valuation Analysis

4.1 Price/Earnings Ratio

  • CDXS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CDXS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CDXS Price Earnings VS Forward Price EarningsCDXS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CDXS Per share dataCDXS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

  • CDXS's earnings are expected to grow with 23.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.57%
EPS Next 3Y23.47%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CDXS Dividend Analysis

5.1 Amount

  • No dividends for CDXS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CDXS Fundamentals: All Metrics, Ratios and Statistics

CODEXIS INC

NASDAQ:CDXS (4/8/2026, 8:21:02 PM)

After market: 2.2 -0.01 (-0.45%)

2.21

+0.23 (+11.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)03-11
Earnings (Next)04-30
Inst Owners73.06%
Inst Owner Change0%
Ins Owners2.44%
Ins Owner Change2%
Market Cap200.82M
Revenue(TTM)70.39M
Net Income(TTM)-43.97M
Analysts81.54
Price Target6.71 (203.62%)
Short Float %12.86%
Short Ratio4.23
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)155.8%
Min EPS beat(2)-45.17%
Max EPS beat(2)356.77%
EPS beat(4)2
Avg EPS beat(4)81.26%
Min EPS beat(4)-45.17%
Max EPS beat(4)356.77%
EPS beat(8)3
Avg EPS beat(8)6.04%
EPS beat(12)5
Avg EPS beat(12)2.71%
EPS beat(16)9
Avg EPS beat(16)12.19%
Revenue beat(2)1
Avg Revenue beat(2)-23.99%
Min Revenue beat(2)-54.44%
Max Revenue beat(2)6.47%
Revenue beat(4)2
Avg Revenue beat(4)-16.23%
Min Revenue beat(4)-54.44%
Max Revenue beat(4)6.53%
Revenue beat(8)4
Avg Revenue beat(8)-7.01%
Revenue beat(12)5
Avg Revenue beat(12)-3.28%
Revenue beat(16)8
Avg Revenue beat(16)-0.51%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-46%
EPS NQ rev (3m)-46%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0.35%
Revenue NQ rev (3m)0.35%
Revenue NY rev (1m)5%
Revenue NY rev (3m)5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.85
P/FCF N/A
P/OCF N/A
P/B 3.97
P/tB 4.18
EV/EBITDA N/A
EPS(TTM)-0.52
EYN/A
EPS(NY)-0.41
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0.77
BVpS0.56
TBVpS0.53
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -29.75%
ROE -87.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.73%
FCFM N/A
ROA(3y)-43.13%
ROA(5y)-30.29%
ROE(3y)-90.86%
ROE(5y)-61.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.12%
GM growth 5Y1.62%
F-Score4
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 85.19%
Cap/Sales 6.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.82
Quick Ratio 3.75
Altman-Z -4.44
F-Score4
WACC11.14%
ROIC/WACCN/A
Cap/Depr(3y)84.1%
Cap/Depr(5y)167.03%
Cap/Sales(3y)6.63%
Cap/Sales(5y)7.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%184.62%
EPS Next Y21.54%
EPS Next 2Y27.57%
EPS Next 3Y23.47%
EPS Next 5Y12.77%
Revenue 1Y (TTM)18.61%
Revenue growth 3Y-20.22%
Revenue growth 5Y0.37%
Sales Q2Q%81.34%
Revenue Next Year10.49%
Revenue Next 2Y12.35%
Revenue Next 3Y16.33%
Revenue Next 5Y25.46%
EBIT growth 1Y34.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year34.61%
EBIT Next 3Y16.57%
EBIT Next 5Y15.12%
FCF growth 1Y55.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.79%
OCF growth 3YN/A
OCF growth 5YN/A

CODEXIS INC / CDXS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for CODEXIS INC?

ChartMill assigns a fundamental rating of 2 / 10 to CDXS.


Can you provide the valuation status for CODEXIS INC?

ChartMill assigns a valuation rating of 1 / 10 to CODEXIS INC (CDXS). This can be considered as Overvalued.


What is the profitability of CDXS stock?

CODEXIS INC (CDXS) has a profitability rating of 1 / 10.